Body Handbook კატალოგი პროფილი რეიტინგი
სუნთქვა BODY HANDBOOK
სუნთქვა · §2
ასთმა: AIR და MART გზა
If you have asthma, you probably carry two inhalers: a blue rescue puffer, and maybe a brown preventer you forget to take. The blue one feels like the safe one. It isn't — it opens your airways and does nothing for the inflammation underneath, and leaning on it heavily tracks with more attacks and higher death rates Nwaru et al. 2020. The global asthma guideline now replaces both with one combination inhaler, where every puff of relief also carries a small anti-inflammatory dose. Used this way, the attacks that end in urgent care or a prednisone course drop by roughly half.
გააკეთე · ყოველდღე მტკიცებულება ძლიერი თავი სუნთქვა

Asthma is an inflammation problem that causes spasms, not the other way round. The blue puffer (salbutamol, a short-acting beta-agonist) pries the airways open in five minutes and touches none of the fire underneath. The preventer steroid tamps the fire down slowly; you feel nothing from a single puff, then feel the attacks that don't happen six weeks later. The inhaler you can feel becomes the one you trust; the one keeping you safe sits unused 1.

One inhaler solves both problems. The reliever becomes a blend of steroid plus formoterol, a bronchodilator that kicks in within one to three minutes. So relief and prevention arrive in the same puff, dosed to whatever your airways need that day 2.

In mild asthma the as-needed combination inhaler cut severe attacks by about two-thirds versus the blue puffer alone 3, and in one trial it beat the older standard of daily preventer plus rescue while asking less of the patient 4. For worse asthma, using the same inhaler daily and on flares cuts emergency-level attacks by roughly a third 5.

What lifts, and roughly when.

  • Two to three weeks: the 4 AM cough stops waking you; the wrecked mornings ease 6.
  • A few months: stairs are just stairs, and the question of whether you can manage exertion drops out of your planning.
  • A year: the bad week doesn't arrive — a cold stays a cold instead of becoming a prednisone course 5.
  • A decade: the oral-steroid side effects you'd have banked (weight, bone-density drift, cataract risk) never accumulate 7.
The fine print — when to skip it, and what people get wrong

The felt experience points at the wrong inhaler. A rising blue-puffer count is the disease worsening, not relief working; three canisters a year is where population-level harm becomes measurable 8.

Generally safe in pregnancy and older age; uncontrolled asthma is the bigger risk 2. Flag unstable heart rhythm or severe uncontrolled hypertension. Children under 12 and an attack that isn't responding both need different handling — a non-responding attack is an emergency call rather than a fifth puff.

It fails when the old blue puffer stays in a drawer and gets grabbed on a flare, when inhaler technique is poor (ask for a spacer and a re-check), or when an upstream driver like allergic rhinitis or home damp keeps the airway irritated no matter the dose.

References
  1. 1Reddel HK, FitzGerald JM, Bateman ED, et al. (2019). GINA 2019: a fundamental change in asthma management. European Respiratory Journal. link
  2. 2GINA (2024). Global Strategy for Asthma Management and Prevention. link
  3. 3O'Byrne PM, FitzGerald JM, Bateman ED, et al. (2018). Inhaled Combined Budesonide–Formoterol as Needed in Mild Asthma. New England Journal of Medicine. link
  4. 4Hardy J, Baggott C, Fingleton J, et al. (2019). Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. The Lancet. link
  5. 5Sobieraj DM, Weeda ER, Nguyen E, et al. (2018). Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis. JAMA. link
  6. 6Beasley R, Holliday M, Reddel HK, et al. (2019). Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma. New England Journal of Medicine. link
  7. 7Sullivan PW, Ghushchyan VH, Globe G, Schatz M (2018). Oral corticosteroid exposure and adverse effects in asthmatic patients. Journal of Allergy and Clinical Immunology. link
  8. 8Nwaru BI, Ekström M, Hasvold P, et al. (2020). Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. European Respiratory Journal. link
·
2